BIOTRICITY INC.: 10-Q filed 2017-08-14
What BIOTRICITY INC. reported in its quarterly report filed 2017-08-14 (fiscal Q1 2018): 17 published measures, 35 facts as tagged in accession 0001511164-17-000511.
This filing
- Form
- 10-Q (quarterly report)
- Filed
- 2017-08-14
- Fiscal period
- fiscal Q1 2018
- Accession
- 0001511164-17-000511 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All BIOTRICITY INC. filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2017-06-30 | 1,241,819 | USD | |
| At 2017-03-31 | 473,512 | USD |
Total liabilities
Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2017-06-30 | 4,781,658 | USD | |
| At 2017-03-31 | 4,858,328 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2017-06-30 | -3,539,838 | USD | |
| At 2017-03-31 | -4,384,816 | USD |
Cash and cash equivalents
Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2017-06-30 | 1,192,832 | USD | |
| At 2017-03-31 | 424,868 | USD | |
| At 2016-06-30 | 33,898 | USD | |
| At 2016-03-31 | 53,643 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2017-04-01 to 2017-06-30 | -2,303,313 | USD | 91 |
| 2016-04-01 to 2016-06-30 | -1,044,607 | USD | 91 |
Operating cash flow
Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2017-04-01 to 2017-06-30 | -1,284,885 | USD | 91 |
| 2016-04-01 to 2016-06-30 | -578,567 | USD | 91 |
Financing cash flow
Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2017-04-01 to 2017-06-30 | 1,926,780 | USD | 91 |
| 2016-04-01 to 2016-06-30 | 673,205 | USD | 91 |
Retained earnings or deficit
Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2017-06-30 | -20,610,528 | USD | |
| At 2017-03-31 | -18,307,215 | USD |
Share-based compensation expense
Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2017-04-01 to 2017-06-30 | 221,078 | USD | 91 |
Current assets
Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2017-06-30 | 1,208,819 | USD | |
| At 2017-03-31 | 440,512 | USD |
Operating expenses
Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2017-04-01 to 2017-06-30 | 1,381,769 | USD | 91 |
| 2016-04-01 to 2016-06-30 | 800,808 | USD | 91 |
Research and development expense
Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2017-04-01 to 2017-06-30 | 315,110 | USD | 91 |
| 2016-04-01 to 2016-06-30 | 266,370 | USD | 91 |
Common shares outstanding
Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2017-06-30 | 21,181,061 | shares | |
| At 2017-03-31 | 18,075,841 | shares |
Additional paid-in capital
Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2017-06-30 | 17,423,384 | USD | |
| At 2017-03-31 | 14,308,583 | USD |
Accumulated other comprehensive income or loss
Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2017-06-30 | -499,874 | USD | |
| At 2017-03-31 | -413,384 | USD |
Accrued current liabilities
Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2017-06-30 | 124,602 | USD | |
| At 2017-03-31 | 271,266 | USD |
General and administrative expense
General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2017-04-01 to 2017-06-30 | 1,066,659 | USD | 91 |
| 2016-04-01 to 2016-06-30 | 534,468 | USD | 91 |
Inspect the source
- Entity
- BIOTRICITY INC. / CIK 0001630113
- Captured
- 2026-09-21T17:22:14.606Z
- SEC response SHA-256
de56e3354d4180362d8bf36a6dd02ff7fd0db9690bc31c81e452959deb9a8d37
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001630113.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))